P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847740.08829.48 |
| _version_ | 1797287242942644224 |
|---|---|
| author | H. Zhu Y. Sha Y. Miao S. Qin W. Wu J. Qiu H. Mi Y. Yang C. Peng C. Ding Z. Wang L. Fan W. Xu J. Li |
| author_facet | H. Zhu Y. Sha Y. Miao S. Qin W. Wu J. Qiu H. Mi Y. Yang C. Peng C. Ding Z. Wang L. Fan W. Xu J. Li |
| author_sort | H. Zhu |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:30:08Z |
| format | Article |
| id | doaj.art-974c310c22324db38dedfd257bc1c5d9 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:30:08Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-974c310c22324db38dedfd257bc1c5d92024-03-02T06:40:33ZengWileyHemaSphere2572-92412022-06-0161105110610.1097/01.HS9.0000847740.08829.48202206003-01105P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)H. Zhu0Y. Sha1Y. Miao2S. Qin3W. Wu4J. Qiu5H. Mi6Y. Yang7C. Peng8C. Ding9Z. Wang10L. Fan11W. Xu12J. Li131 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University2 Department of Hematology, Pukou CLL Center, Pukou division of Jiangsu Province Hospital2 Department of Hematology, Pukou CLL Center, Pukou division of Jiangsu Province Hospital2 Department of Hematology, Pukou CLL Center, Pukou division of Jiangsu Province Hospital2 Department of Hematology, Pukou CLL Center, Pukou division of Jiangsu Province Hospital3 Department of Nuclear Medicine4 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical Universityhttp://journals.lww.com/10.1097/01.HS9.0000847740.08829.48 |
| spellingShingle | H. Zhu Y. Sha Y. Miao S. Qin W. Wu J. Qiu H. Mi Y. Yang C. Peng C. Ding Z. Wang L. Fan W. Xu J. Li P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) HemaSphere |
| title | P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) |
| title_full | P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) |
| title_fullStr | P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) |
| title_full_unstemmed | P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) |
| title_short | P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) |
| title_sort | p1219 zanubrutinib lenalidomide plus r chop zr2 chop as the first line treatment for non gcb diffused large b cell lymphoma dlbcl |
| url | http://journals.lww.com/10.1097/01.HS9.0000847740.08829.48 |
| work_keys_str_mv | AT hzhu p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT ysha p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT ymiao p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT sqin p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT wwu p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT jqiu p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT hmi p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT yyang p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT cpeng p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT cding p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT zwang p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT lfan p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT wxu p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl AT jli p1219zanubrutiniblenalidomideplusrchopzr2chopasthefirstlinetreatmentfornongcbdiffusedlargebcelllymphomadlbcl |